• Alpha Tau announced the first Alpha DaRT treatment of a recurrent glioblastoma patient in Israel, marking the first use outside the US.
• The procedure was completed safely, with no unexpected complications, using a brain-specific delivery system to place sources into the tumor.
• The patient tolerated the treatment well, supporting feasibility for use in a setting with no established standard of care at recurrence.
• The case was performed under the ALL broad-access clinical protocol at Hadassah University Medical Center.
• US clinical results were already presented via interim data from the REGAIN recurrent glioblastoma trial; enrollment is continuing following FDA clearance to proceed to full enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230830PRIMZONEFULLFEED9750626) on June 23, 2026, and is solely responsible for the information contained therein.